CoChat
Sign Up
Cited by 455Immune cells in cancerImmunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer

Open access
Law, Andrew M. K., Valdes-Mora, Fatima, Gallego-Ortega, David·2020·Cells
DOI 10.3390/cells9030561PMC PMC7140518
Open this paper in CoChat — free account

Abstract

The emergence of immunotherapy has been an astounding breakthrough in cancer treatments. In particular, immune checkpoint inhibitors, targeting PD-1 and CTLA-4, have shown remarkable therapeutic outcomes. However, response rates from immunotherapy have been reported to be varied, with some having pronounced success and others with minimal to no clinical benefit. An important aspect associated with this discrepancy in patient response is the immune-suppressive effects elicited by the tumour microenvironment (TME). Immune suppression plays a pivotal role in regulating cancer progression, metastasis, and reducing immunotherapy success. Most notably, myeloid-derived suppressor cells (MDSC), a heterogeneous population of immature myeloid cells, have potent mechanisms to inhibit T-cell and NK-cell activity to promote tumour growth, development of the pre-metastatic niche, and contribute to resistance to immunotherapy. Accumulating research indicates that MDSC can be a therapeutic target to alleviate their pro-tumourigenic functions and immunosuppressive activities to bolster the efficacy of checkpoint inhibitors. In this review, we provide an overview of the general immunotherapeutic approaches and discuss the characterisation, expansion, and activities of MDSCs with the current treatments used to target them either as a single therapeutic target or synergistically in combination with immunotherapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cells9030561

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Presence of TAMs, TANs, MDSC, and Tregs in the TME is associated with poor prognosis and outcome in many oncological conditions, as they produce IL-10, TGF-β, and prostaglandins that suppress anti-tumor activities of NK, T, and B cells, allowing survival and proliferation of cancer cells.

    “In many oncological conditions as reviewed in (26) and (54), the presence of tumor-associated macrophages (TAMs), tumor-associated neutrophils (TANs), myeloid-derived suppressor cells (MDSC), and regulatory T cells (Tregs) in the TME is associated with poor prognosis and outcome, as they produce IL-10, TGF-β, and prostaglandins that are potent immunosuppressors, suppressing the anti-tumor activi”

    From Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis (2021) · cites this paper as [54]

    Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 235

  1. [1]Garcia-Lora A. Algarra I. Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape J. Cell Physiol. 2003 195 346 355 10.1002/jcp.10290 12704644 · DOI
  2. [2]Fernald K. Kurokawa M. Evading apoptosis in cancer Trends Cell Biol. 2013 23 620 633 10.1016/j.tcb.2013.07.006 23958396 PMC4091735 · DOI
  3. [3]Burkholder B. Tumor-induced perturbations of cytokines and immune cell networks Biochim. Biophys. Acta 2014 1845 182 201 10.1016/j.bbcan.2014.01.004 24440852 · DOI
  4. [4]Salgado R. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014 Ann. Oncol. 2015 26 259 271 10.1093/annonc/mdu450 25214542 PMC6267863 · DOI
  5. [5]Chow M.T. Moller A. Smyth M.J. Inflammation and immune surveillance in cancer Semin Cancer Biol. 2012 22 23 32 10.1016/j.semcancer.2011.12.004 22210181 · DOI
  6. [6]Valdes-Mora F. Single-Cell Transcriptomics in Cancer Immunobiology: The Future of Precision Oncology Front. Immunol. 2018 9 2582 10.3389/fimmu.2018.02582 30483257 PMC6240655 · DOI
  7. [7]Lollini P.L. The Promise of Preventive Cancer Vaccines Vaccines (Basel) 2015 3 467 489 10.3390/vaccines3020467 26343198 PMC4494347 · DOI
  8. [8]Zhang H. Chen J. Current status and future directions of cancer immunotherapy J. Cancer 2018 9 1773 1781 10.7150/jca.24577 29805703 PMC5968765 · DOI
  9. [9]Lim S.G. Prevention of hepatocellular carcinoma in hepatitis B virus infection J. Gastroenterol. Hepatol. 2009 24 1352 1357 10.1111/j.1440-1746.2009.05985.x 19702903 · DOI
  10. [10]Mahdavi A. Monk B.J. Vaccines against human papillomavirus and cervical cancer: Promises and challenges Oncologist 2005 10 528 538 10.1634/theoncologist.10-7-528 16079320 · DOI
  11. [11]Vigneron N. Human Tumor Antigens and Cancer Immunotherapy Biomed. Res. Int. 2015 2015 948501 10.1155/2015/948501 26161423 PMC4487697 · DOI
  12. [12]Hutchison S. Pritchard A.L. Identifying neoantigens for use in immunotherapy Mamm. Genome 2018 29 714 730 10.1007/s00335-018-9771-6 30167844 PMC6267674 · DOI
  13. [13]Vermaelen K. Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses Front. Immunol. 2019 10 8 10.3389/fimmu.2019.00008 30723469 PMC6349827 · DOI
  14. [14]Mougel A. Terme M. Tanchot C. Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade Front. Immunol. 2019 10 467 10.3389/fimmu.2019.00467 30923527 PMC6426771 · DOI
  15. [15]Hollingsworth R.E. Jansen K. Turning the corner on therapeutic cancer vaccines NPJ Vaccines 2019 4 7 10.1038/s41541-019-0103-y 30774998 PMC6368616 · DOI · Paper page
  16. [16]Karlitepe A. Ozalp O. Avci C.B. New approaches for cancer immunotherapy Tumour Biol. 2015 36 4075 4078 10.1007/s13277-015-3491-2 25934338 · DOI
  17. [17]Dahlen E. Veitonmaki N. Norlen P. Bispecific antibodies in cancer immunotherapy Ther. Adv. Vaccines Immunother. 2018 6 3 17 10.1177/2515135518763280 29998217 PMC5933537 · DOI
  18. [18]Vu T. Claret F.X. Trastuzumab: Updated mechanisms of action and resistance in breast cancer Front. Oncol. 2012 2 62 22720269 PMC3376449
  19. [19]McKeage K. Perry C.M. Trastuzumab: A review of its use in the treatment of metastatic breast cancer overexpressing HER2 Drugs 2002 62 209 243 10.2165/00003495-200262010-00008 11790161 · DOI
  20. [20]Met O. Principles of adoptive T cell therapy in cancer Semin Immunopathol. 2019 41 49 58 10.1007/s00281-018-0703-z 30187086 · DOI
  21. [21]Dudley M.E. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes Science 2002 298 850 854 10.1126/science.1076514 12242449 PMC1764179 · DOI · Paper page
  22. [22]Rosenberg S.A. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy Clin. Cancer Res. 2011 17 4550 4557 10.1158/1078-0432.CCR-11-0116 21498393 PMC3131487 · DOI
  23. [23]Besser M.J. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: Intent-to-treat analysis and efficacy after failure to prior immunotherapies Clin. Cancer Res. 2013 19 4792 4800 10.1158/1078-0432.CCR-13-0380 23690483 · DOI
  24. [24]Lee H.J. Expansion of tumor-infiltrating lymphocytes and their potential for application as adoptive cell transfer therapy in human breast cancer Oncotarget 2017 8 113345 113359 10.18632/oncotarget.23007 29371915 PMC5768332 · DOI
  25. [25]Houot R. T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition Cancer Immunol. Res. 2015 3 1115 1122 10.1158/2326-6066.CIR-15-0190 26438444 · DOI
  26. [26]Rohaan M.W. Wilgenhof S. Haanen J. Adoptive cellular therapies: The current landscape Virchows Arch. 2019 474 449 461 10.1007/s00428-018-2484-0 30470934 PMC6447513 · DOI
  27. [27]June C.H. Riddell S.R. Schumacher T.N. Adoptive cellular therapy: A race to the finish line Sci. Transl. Med. 2015 7 280ps7 10.1126/scitranslmed.aaa3643 25810311 · DOI
  28. [28]Maude S.L. Shpall E.J. Grupp S.A. Chimeric antigen receptor T-cell therapy for ALL Hematol. Am. Soc. Hematol. Educ. Program. 2014 2014 559 564 10.1182/asheducation-2014.1.559 25696911 · DOI
  29. [29]Pehlivan K.C. Duncan B.B. Lee D.W. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease Curr. Hematol. Malig. Rep. 2018 13 396 406 10.1007/s11899-018-0470-x 30120708 · DOI
  30. [30]Gattinoni L. Adoptive T cell transfer: Imagining the next generation of cancer immunotherapies Semin. Immunol. 2016 28 1 2 10.1016/j.smim.2016.03.019 27161516 PMC6377561 · DOI
  31. [31]Li J. Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: Lessons learned and strategies for moving forward J. Hematol. Oncol. 2018 11 22 10.1186/s13045-018-0568-6 29433552 PMC5809840 · DOI
  32. [32]Chu F. Cao J. Neelalpu S.S. Versatile CAR T-cells for cancer immunotherapy Contemp. Oncol. (Pozn) 2018 22 73 80 10.5114/wo.2018.73892 29628798 PMC5885071 · DOI
  33. [34]Guo Z.S. The 2018 Nobel Prize in medicine goes to cancer immunotherapy (editorial for BMC cancer) BMC Cancer 2018 18 1086 10.1186/s12885-018-5020-3 30415640 PMC6231274 · DOI
  34. [35]Sambi M. Bagheri L. Szewczuk M.R. Current Challenges in Cancer Immunotherapy: Multimodal Approaches to Improve Efficacy and Patient Response Rates J. Oncol. 2019 2019 4508794 10.1155/2019/4508794 30941175 PMC6420990 · DOI
  35. [36]Escors D. Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy New J. Sci. 2014 2014 10.1155/2014/734515 PMC3952940 24634791 · DOI
  36. [37]Lipson E.J. Antagonists of PD-1 and PD-L1 in Cancer Treatment Semin. Oncol. 2015 42 587 600 10.1053/j.seminoncol.2015.05.013 26320063 PMC4555873 · DOI
  37. [38]Nanda R. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study J. Clin. Oncol. 2016 34 2460 2467 10.1200/JCO.2015.64.8931 27138582 PMC6816000 · DOI · Paper page
  38. [39]Ventola C.L. Cancer Immunotherapy, Part 3: Challenges and Future Trends Pharm. Ther. 2017 42 514 521 PMC5521300 28781505
  39. [40]Rugo H.S. Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer Clin. Cancer Res. 2018 24 2804 2811 10.1158/1078-0432.CCR-17-3452 29559561 · DOI
  40. [41]Yang L. Recognizing and managing on toxicities in cancer immunotherapy Tumour Biol. 2017 39 1010428317694542 10.1177/1010428317694542 28351299 · DOI
  41. [42]Nikanjam M. Patel H. Kurzrock R. Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns Oncoimmunology 2017 6 e1338997 10.1080/2162402X.2017.1338997 28920006 PMC5593707 · DOI
  42. [44]Tuccitto A. Immunosuppressive circuits in tumor microenvironment and their influence on cancer treatment efficacy Virchows Arch. 2019 474 407 420 10.1007/s00428-018-2477-z 30374798 · DOI
  43. [45]Yang L. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis Cancer Cell 2004 6 409 421 10.1016/j.ccr.2004.08.031 15488763 · DOI · Paper page
  44. [46]Motz G.T. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors Nat. Med. 2014 20 607 615 10.1038/nm.3541 24793239 PMC4060245 · DOI
  45. [48]Disis M.L. Immune regulation of cancer J. Clin. Oncol. 2010 28 4531 4538 10.1200/JCO.2009.27.2146 20516428 PMC3041789 · DOI
  46. [49]Frydrychowicz M. The Dual Role of Treg in Cancer Scand. J. Immunol. 2017 86 436 443 10.1111/sji.12615 28941312 · DOI
  47. [50]Takeuchi Y. Nishikawa H. Roles of regulatory T cells in cancer immunity Int. Immunol. 2016 28 401 409 10.1093/intimm/dxw025 27160722 PMC4986235 · DOI
  48. [51]Weber R. Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors Front. Immunol. 2018 9 1310 10.3389/fimmu.2018.01310 29942309 PMC6004385 · DOI
  49. [52]Gabrilovich D.I. Myeloid-Derived Suppressor Cells Cancer Immunol. Res. 2017 5 3 8 10.1158/2326-6066.CIR-16-0297 28052991 PMC5426480 · DOI
  50. [53]Takizawa H. Boettcher S. Manz M.G. Demand-adapted regulation of early hematopoiesis in infection and inflammation Blood 2012 119 2991 3002 10.1182/blood-2011-12-380113 22246037 · DOI
  51. [54]de Haas N. Improving cancer immunotherapy by targeting the STATe of MDSCs Oncoimmunology 2016 5 e1196312 10.1080/2162402X.2016.1196312 27622051 PMC5006927 · DOI
  52. [55]Gabrilovich D.I. Ostrand-Rosenberg S. Bronte V. Coordinated regulation of myeloid cells by tumours Nat. Rev. Immunol. 2012 12 253 268 10.1038/nri3175 22437938 PMC3587148 · DOI · Paper page
  53. [56]Umansky V. The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression Vaccines (Basel) 2016 4 36 10.3390/vaccines4040036 27827871 PMC5192356 · DOI
  54. [57]Meirow Y. Kanterman J. Baniyash M. Paving the Road to Tumor Development and Spreading: Myeloid-Derived Suppressor Cells are Ruling the Fate Front. Immunol. 2015 6 523 10.3389/fimmu.2015.00523 26528286 PMC4601280 · DOI
  55. [58]Sawanobori Y. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice Blood 2008 111 5457 5466 10.1182/blood-2008-01-136895 18375791 · DOI
  56. [59]Ostrand-Rosenberg S. Sinha P. Myeloid-derived suppressor cells: Linking inflammation and cancer J. Immunol. 2009 182 4499 4506 10.4049/jimmunol.0802740 19342621 PMC2810498 · DOI
  57. [60]Sica A. Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development J. Clin. Invest. 2007 117 1155 1166 10.1172/JCI31422 17476345 PMC1857267 · DOI
  58. [61]Condamine T. Mastio J. Gabrilovich D.I. Transcriptional regulation of myeloid-derived suppressor cells J. Leukoc. Biol. 2015 98 913 922 10.1189/jlb.4RI0515-204R 26337512 PMC4661041 · DOI
  59. [62]Yan H.H. Gr-1+CD11b+ myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung Cancer Res. 2010 70 6139 6149 10.1158/0008-5472.CAN-10-0706 20631080 PMC4675145 · DOI
  60. [63]Gao D. Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition Cancer Res. 2012 72 1384 1394 10.1158/0008-5472.CAN-11-2905 22282653 PMC8543151 · DOI
  61. [65]Sceneay J. Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche Cancer Res. 2012 72 3906 3911 10.1158/0008-5472.CAN-11-3873 22751463 · DOI
  62. [66]Zhang S. The Role of Myeloid-Derived Suppressor Cells in Patients with Solid Tumors: A Meta-Analysis PLoS ONE 2016 11 e0164514 10.1371/journal.pone.0164514 27780254 PMC5079654 · DOI
  63. [67]Law A.M. The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy Endocr. Relat. Cancer 2017 24 R123 R144 10.1530/ERC-16-0404 28193698 PMC5425956 · DOI
  64. [68]Solito S. Myeloid-derived suppressor cell heterogeneity in human cancers Ann. N Y Acad. Sci. 2014 1319 47 65 10.1111/nyas.12469 24965257 · DOI
  65. [69]Vetsika E.K. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients J. Immunol. Res. 2014 2014 659294 10.1155/2014/659294 25436215 PMC4243712 · DOI
  66. [71]Obermajer N. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells Blood 2011 118 5498 5505 10.1182/blood-2011-07-365825 21972293 PMC3217352 · DOI
  67. [72]Diaz-Montero C.M. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy Cancer Immunol. Immunother. 2009 58 49 59 10.1007/s00262-008-0523-4 18446337 PMC3401888 · DOI
  68. [73]Zhao F. S100A9 a new marker for monocytic human myeloid-derived suppressor cells Immunology 2012 136 176 183 10.1111/j.1365-2567.2012.03566.x 22304731 PMC3403264 · DOI
  69. [74]Trikha P. Carson W.E. 3rd Signaling pathways involved in MDSC regulation Biochim. Biophys. Acta 2014 1846 55 65 24727385 PMC4140957
  70. [75]Lesokhin A.M. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment Cancer Res. 2012 72 876 886 10.1158/0008-5472.CAN-11-1792 22174368 PMC3288305 · DOI
  71. [76]Liang H. Host STING-dependent MDSC mobilization drives extrinsic radiation resistance Nat. Commun. 2017 8 1736 10.1038/s41467-017-01566-5 29170400 PMC5701019 · DOI
  72. [77]Blattner C. CCR5(+) Myeloid-Derived Suppressor Cells Are Enriched and Activated in Melanoma Lesions Cancer Res. 2018 78 157 167 10.1158/0008-5472.CAN-17-0348 29089297 · DOI
  73. [78]Umansky V. CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma Cancer Immunol. Immunother. 2017 66 1015 1023 10.1007/s00262-017-1988-9 28382399 PMC11029643 · DOI
  74. [79]Metelitsa L.S. Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans Clin. Immunol. 2011 140 119 129 10.1016/j.clim.2010.10.005 21095162 PMC3444285 · DOI
  75. [80]Youn J.I. Gabrilovich D.I. The biology of myeloid-derived suppressor cells: The blessing and the curse of morphological and functional heterogeneity Eur. J. Immunol. 2010 40 2969 2975 10.1002/eji.201040895 21061430 PMC3277452 · DOI
  76. [81]Youn J.I. Subsets of myeloid-derived suppressor cells in tumor-bearing mice J. Immunol. 2008 181 5791 5802 10.4049/jimmunol.181.8.5791 18832739 PMC2575748 · DOI
  77. [82]Karakasheva T.A. CD38-Expressing Myeloid-Derived Suppressor Cells Promote Tumor Growth in a Murine Model of Esophageal Cancer Cancer Res. 2015 75 4074 4085 10.1158/0008-5472.CAN-14-3639 26294209 PMC4592477 · DOI
  78. [83]Ryzhov S. Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells J. Immunol. 2011 187 6120 6129 10.4049/jimmunol.1101225 22039302 PMC3221925 · DOI
  79. [84]Umansky V. Extracellular adenosine metabolism in immune cells in melanoma Cancer Immunol. Immunother. 2014 63 1073 1080 10.1007/s00262-014-1553-8 24756420 PMC11029545 · DOI
  80. [85]Wang W. Functional characterization of myeloid-derived suppressor cell subpopulations during the development of experimental arthritis Eur. J. Immunol. 2015 45 464 473 10.1002/eji.201444799 25352399 · DOI
  81. [86]Ding Y. CD40 controls CXCR5-induced recruitment of myeloid-derived suppressor cells to gastric cancer Oncotarget 2015 6 38901 38911 10.18632/oncotarget.5644 26462153 PMC4770745 · DOI
  82. [87]Pan P.Y. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer Cancer Res. 2010 70 99 108 10.1158/0008-5472.CAN-09-1882 19996287 PMC2805053 · DOI
  83. [88]Shen J. Downregulation of CD40 expression contributes to the accumulation of myeloid-derived suppressor cells in gastric tumors Oncol Lett. 2014 8 775 780 10.3892/ol.2014.2174 25009656 PMC4081434 · DOI
  84. [89]Cho W.K. Immunomodulatory effect of captopril and local irradiation on myeloid-derived suppressor cells Radiat. Oncol. J. 2016 34 223 229 10.3857/roj.2016.01816 27609109 PMC5066444 · DOI
  85. [90]Gallego-Ortega D. ELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor Cells PLoS Biol. 2015 13 e1002330 10.1371/journal.pbio.1002330 26717410 PMC4696735 · DOI
  86. [91]Haile L.A. CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice J. Immunol. 2010 185 203 210 10.4049/jimmunol.0903573 20525890 · DOI
  87. [92]Ostrand-Rosenberg S. Myeloid-derived suppressor cells: More mechanisms for inhibiting antitumor immunity Cancer Immunol. Immunother. 2010 59 1593 1600 10.1007/s00262-010-0855-8 20414655 PMC3706261 · DOI
  88. [93]Lacotte S. Impact of myeloid-derived suppressor cell on Kupffer cells from mouse livers with hepatocellular carcinoma Oncoimmunology 2016 5 e1234565 10.1080/2162402X.2016.1234565 27999748 PMC5139644 · DOI
  89. [94]Marigo I. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor Immunity 2010 32 790 802 10.1016/j.immuni.2010.05.010 20605485 · DOI
  90. [95]Liechtenstein T. A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice Oncotarget 2014 5 7843 7857 10.18632/oncotarget.2279 25151659 PMC4202165 · DOI
  91. [96]Dong H.Y. Wilkes S. Yang H. CD71 is selectively and ubiquitously expressed at high levels in erythroid precursors of all maturation stages: A comparative immunochemical study with glycophorin A and hemoglobin A Am. J. Surg. Pathol. 2011 35 723 732 10.1097/PAS.0b013e31821247a8 21415701 · DOI
  92. [97]Movahedi K. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity Blood 2008 111 4233 4244 10.1182/blood-2007-07-099226 18272812 · DOI
  93. [98]Bunt S.K. Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4 J. Leukoc. Biol. 2009 85 996 1004 10.1189/jlb.0708446 19261929 PMC2698586 · DOI
  94. [99]Sansom D.M. CD28, CTLA-4 and their ligands: Who does what and to whom? Immunology 2000 101 169 177 10.1046/j.1365-2567.2000.00121.x 11012769 PMC2327073 · DOI
  95. [100]Yang R. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells Cancer Res. 2006 66 6807 6815 10.1158/0008-5472.CAN-05-3755 16818658 · DOI
  96. [101]Yang Y. LPS converts Gr-1(+)CD115(+) myeloid-derived suppressor cells from M2 to M1 via P38 MAPK Exp. Cell Res. 2013 319 1774 1783 10.1016/j.yexcr.2013.05.007 23701951 · DOI
  97. [102]Youn J.I. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice J. Leukoc. Biol. 2012 91 167 181 10.1189/jlb.0311177 21954284 PMC3250305 · DOI
  98. [103]Albeituni S.H. Ding C. Yan J. Hampering immune suppressors: Therapeutic targeting of myeloid-derived suppressor cells in cancer Cancer J. 2013 19 490 501 10.1097/PPO.0000000000000006 24270348 PMC3902636 · DOI
  99. [104]Tang R. M-CSF (monocyte colony stimulating factor) and M-CSF receptor expression by breast tumour cells: M-CSF mediated recruitment of tumour infiltrating monocytes? J. Cell Biochem. 1992 50 350 356 10.1002/jcb.240500403 1334964 · DOI
  100. [105]Hu X. Transmembrane TNF-alpha promotes suppressive activities of myeloid-derived suppressor cells via TNFR2 J. Immunol. 2014 192 1320 1331 10.4049/jimmunol.1203195 24379122 · DOI
  101. [106]Mandruzzato S. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients J. Immunol. 2009 182 6562 6568 10.4049/jimmunol.0803831 19414811 · DOI
  102. [107]Sinha P. Tumor-induced myeloid-derived suppressor cell function is independent of IFN-gamma and IL-4Ralpha Eur. J. Immunol. 2012 42 2052 2059 10.1002/eji.201142230 22673957 PMC3673533 · DOI
  103. [108]Gallina G. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells J. Clin. Invest. 2006 116 2777 2790 10.1172/JCI28828 17016559 PMC1578632 · DOI
  104. [109]Roth F. Aptamer-mediated blockade of IL4Ralpha triggers apoptosis of MDSCs and limits tumor progression Cancer Res. 2012 72 1373 1383 10.1158/0008-5472.CAN-11-2772 22282665 · DOI
  105. [110]Schouppe E. Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events Eur. J. Immunol. 2013 43 2930 2942 10.1002/eji.201343349 23878002 · DOI
  106. [111]Goldmann O. Beineke A. Medina E. Identification of a Novel Subset of Myeloid-Derived Suppressor Cells During Chronic Staphylococcal Infection That Resembles Immature Eosinophils J. Infect. Dis. 2017 216 1444 1451 10.1093/infdis/jix494 29029332 · DOI
  107. [112]Georgoudaki A.M. CD244 is expressed on dendritic cells and regulates their functions Immunol. Cell Biol. 2015 93 581 590 10.1038/icb.2014.124 25643613 · DOI
  108. [113]Lu C. The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells Oncoimmunology 2016 5 e1247135 10.1080/2162402X.2016.1247135 28123883 PMC5214087 · DOI
  109. [114]Lee C.R. Myeloid-Derived Suppressor Cells Are Controlled by Regulatory T Cells via TGF-beta during Murine Colitis Cell Rep. 2016 17 3219 3232 10.1016/j.celrep.2016.11.062 28009291 · DOI
  110. [115]Chiu D.K. Hypoxia induces myeloid-derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C-C motif) ligand 26 Hepatology 2016 64 797 813 10.1002/hep.28655 27228567 · DOI · Paper page
  111. [116]Hart K.M. Phenotypic and functional delineation of murine CX(3)CR1 monocyte-derived cells in ovarian cancer Neoplasia 2009 11 564 573 10.1593/neo.09228 19484145 PMC2685445 · DOI
  112. [117]Zhao W. Subsets of myeloid-derived suppressor cells in hepatocellular carcinoma express chemokines and chemokine receptors differentially Int. Immunopharmacol. 2015 26 314 321 10.1016/j.intimp.2015.04.010 25891236 · DOI
  113. [118]Katoh H. CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis Cancer Cell 2013 24 631 644 10.1016/j.ccr.2013.10.009 24229710 PMC3928012 · DOI · Paper page
  114. [119]O’Connor M.A. Subpopulations of M-MDSCs from mice infected by an immunodeficiency-causing retrovirus and their differential suppression of T- vs B-cell responses Virology 2015 485 263 273 10.1016/j.virol.2015.07.020 26318248 PMC6553456 · DOI
  115. [120]Ortiz M.L. Myeloid-derived suppressor cells in the development of lung cancer Cancer Immunol. Res. 2014 2 50 58 10.1158/2326-6066.CIR-13-0129 24778162 PMC4007346 · DOI
  116. [121]Wang T. Galectin-3 contributes to cisplatin-induced myeloid derived suppressor cells (MDSCs) recruitment in Lewis lung cancer-bearing mice Mol. Biol. Rep. 2014 41 4069 4076 10.1007/s11033-014-3276-5 24615503 · DOI
  117. [122]Pyzer A.R. Myeloid-derived suppressor cells as effectors of immune suppression in cancer Int. J. Cancer 2016 139 1915 1926 10.1002/ijc.30232 27299510 · DOI
  118. [123]Talmadge J.E. Gabrilovich D.I. History of myeloid-derived suppressor cells Nat. Rev. Cancer 2013 13 739 752 10.1038/nrc3581 24060865 PMC4358792 · DOI · Paper page
  119. [124]Nagaraj S. Antigen-specific CD4(+) T cells regulate function of myeloid-derived suppressor cells in cancer via retrograde MHC class II signaling Cancer Res. 2012 72 928 938 10.1158/0008-5472.CAN-11-2863 22237629 PMC4062074 · DOI
  120. [125]Sato Y. Characterization of the myeloid-derived suppressor cell subset regulated by NK cells in malignant lymphoma Oncoimmunology 2015 4 e995541 10.1080/2162402X.2014.995541 25949922 PMC4404816 · DOI
  121. [126]Zoglmeier C. CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice Clin. Cancer Res. 2011 17 1765 1775 10.1158/1078-0432.CCR-10-2672 21233400 · DOI
  122. [127]Horikawa N. Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells Clin. Cancer Res. 2017 23 587 599 10.1158/1078-0432.CCR-16-0387 27401249 · DOI
  123. [128]Kumar V. The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment Trends Immunol. 2016 37 208 220 10.1016/j.it.2016.01.004 26858199 PMC4775398 · DOI · Paper page
  124. [129]Huang B. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers Cancer Lett. 2007 252 86 92 10.1016/j.canlet.2006.12.012 17257744 · DOI · Paper page
  125. [130]Obermajer N. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment Cancer Res. 2011 71 7463 7470 10.1158/0008-5472.CAN-11-2449 22025564 PMC4993027 · DOI
  126. [132]Zhang J. CD13(hi) Neutrophil-like myeloid-derived suppressor cells exert immune suppression through Arginase 1 expression in pancreatic ductal adenocarcinoma Oncoimmunology 2017 6 e1258504 10.1080/2162402X.2016.1258504 28344866 PMC5353902 · DOI
  127. [133]Resheq Y.J. Impaired Transmigration of Myeloid-Derived Suppressor Cells across Human Sinusoidal Endothelium Is Associated with Decreased Expression of CD13 J. Immunol. 2017 199 1672 1681 10.4049/jimmunol.1600466 28739875 · DOI
  128. [134]Haziot A. Tsuberi B.Z. Goyert S.M. Neutrophil CD14: Biochemical properties and role in the secretion of tumor necrosis factor-alpha in response to lipopolysaccharide J. Immunol. 1993 150 5556 5565 7685797
  129. [135]Damuzzo V. Complexity and challenges in defining myeloid-derived suppressor cells Cytometry B Clin. Cytom. 2015 88 77 91 10.1002/cytob.21206 25504825 PMC4405078 · DOI
  130. [136]Romano A. Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy Br. J. Haematol. 2015 168 689 700 10.1111/bjh.13198 25376846 · DOI
  131. [137]Karakasheva T.A. CD38+ M-MDSC expansion characterizes a subset of advanced colorectal cancer patients JCI Insight 2018 3 10.1172/jci.insight.97022 PMC5926906 29563330 · DOI
  132. [138]Li L. Metformin-Induced Reduction of CD39 and CD73 Blocks Myeloid-Derived Suppressor Cell Activity in Patients with Ovarian Cancer Cancer Res. 2018 78 1779 1791 10.1158/0008-5472.CAN-17-2460 29374065 PMC5882589 · DOI
  133. [140]Rodriguez P.C. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes Cancer Res. 2009 69 1553 1560 10.1158/0008-5472.CAN-08-1921 19201693 PMC2900845 · DOI
  134. [141]Shao X. Distinct alterations of CD68(+)CD163(+) M2-like macrophages and myeloid-derived suppressor cells in newly diagnosed primary immune thrombocytopenia with or without CR after high-dose dexamethasone treatment J. Transl. Med. 2018 16 48 10.1186/s12967-018-1424-8 29499727 PMC5833082 · DOI
  135. [142]Bergenfelz C. Systemic Monocytic-MDSCs Are Generated from Monocytes and Correlate with Disease Progression in Breast Cancer Patients PLoS ONE 2015 10 e0127028 10.1371/journal.pone.0127028 25992611 PMC4439153 · DOI
  136. [144]Poschke I. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign Cancer Res. 2010 70 4335 4345 10.1158/0008-5472.CAN-09-3767 20484028 · DOI
  137. [145]Ju X. The Analysis of CD83 Expression on Human Immune Cells Identifies a Unique CD83+-Activated T Cell Population J. Immunol. 2016 197 4613 4625 10.4049/jimmunol.1600339 27837105 · DOI
  138. [146]Zhang B. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma PLoS ONE 2013 8 e57114 10.1371/journal.pone.0057114 23437326 PMC3577767 · DOI
  139. [147]OuYang L.Y. Tumor-induced myeloid-derived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer J. Transl. Med. 2015 13 47 10.1186/s12967-015-0410-7 25638150 PMC4357065 · DOI
  140. [148]Kohanbash G. GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-alpha Cancer Res. 2013 73 6413 6423 10.1158/0008-5472.CAN-12-4124 24030977 PMC3829000 · DOI
  141. [149]Seo E.H. Association of Chemokines and Chemokine Receptor Expression with Monocytic-Myeloid-Derived Suppressor Cells during Tumor Progression Immune Netw 2018 18 e23 10.4110/in.2018.18.e23 29984041 PMC6026688 · DOI
  142. [151]Kusmartsev S. Oxidative stress regulates expression of VEGFR1 in myeloid cells: Link to tumor-induced immune suppression in renal cell carcinoma J. Immunol. 2008 181 346 353 10.4049/jimmunol.181.1.346 18566400 · DOI
  143. [152]Kitamura T. CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages J. Exp. Med. 2015 212 1043 1059 10.1084/jem.20141836 26056232 PMC4493415 · DOI
  144. [153]Yu J. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer J. Immunol. 2013 190 3783 3797 10.4049/jimmunol.1201449 23440412 · DOI
  145. [154]Qian B.Z. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis Nature 2011 475 222 225 10.1038/nature10138 21654748 PMC3208506 · DOI · Paper page
  146. [156]Reichel C.A. C-C motif chemokine CCL3 and canonical neutrophil attractants promote neutrophil extravasation through common and distinct mechanisms Blood 2012 120 880 890 10.1182/blood-2012-01-402164 22674804 · DOI
  147. [157]Condamine T. Regulation of tumor metastasis by myeloid-derived suppressor cells Annu. Rev. Med. 2015 66 97 110 10.1146/annurev-med-051013-052304 25341012 PMC4324727 · DOI
  148. [158]Hiratsuka S. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis Nat. Cell Biol. 2006 8 1369 1375 10.1038/ncb1507 17128264 · DOI
  149. [159]Steele C.W. CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma Cancer Cell 2016 29 832 845 10.1016/j.ccell.2016.04.014 27265504 PMC4912354 · DOI
  150. [160]Nefedova Y. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer J. Immunol. 2004 172 464 474 10.4049/jimmunol.172.1.464 14688356 · DOI · Paper page
  151. [161]Arai K. S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast Curr. Cancer Drug Targets 2008 8 243 252 10.2174/156800908784533445 18537548 · DOI
  152. [162]Sinha P. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells J. Immunol. 2008 181 4666 4675 10.4049/jimmunol.181.7.4666 18802069 PMC2810501 · DOI
  153. [163]Wang L. Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins J. Immunol. 2013 190 794 804 10.4049/jimmunol.1202088 23248262 · DOI
  154. [164]Kumar V. CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation Immunity 2016 44 303 315 10.1016/j.immuni.2016.01.014 26885857 PMC4759655 · DOI · Paper page
  155. [166]Liu G. SIRT1 limits the function and fate of myeloid-derived suppressor cells in tumors by orchestrating HIF-1alpha-dependent glycolysis Cancer Res. 2014 74 727 737 10.1158/0008-5472.CAN-13-2584 24351289 · DOI
  156. [168]Huang B. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host Cancer Res. 2006 66 1123 1131 10.1158/0008-5472.CAN-05-1299 16424049 · DOI · Paper page
  157. [169]Srivastava M.K. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine Cancer Res. 2010 70 68 77 10.1158/0008-5472.CAN-09-2587 20028852 PMC2805057 · DOI
  158. [170]Fletcher M. l-Arginine depletion blunts antitumor T-cell responses by inducing myeloid-derived suppressor cells Cancer Res. 2015 75 275 283 10.1158/0008-5472.CAN-14-1491 25406192 PMC4297565 · DOI
  159. [172]Bingisser R.M. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway J. Immunol. 1998 160 5729 5734 9637481
  160. [173]Rivoltini L. Immunity to cancer: Attack and escape in T lymphocyte-tumor cell interaction Immunol. Rev. 2002 188 97 113 10.1034/j.1600-065X.2002.18809.x 12445284 · DOI
  161. [174]Rodriguez P.C. Quiceno D.G. Ochoa A.C. L-arginine availability regulates T-lymphocyte cell-cycle progression Blood 2007 109 1568 1573 10.1182/blood-2006-06-031856 17023580 PMC1794048 · DOI · Paper page
  162. [175]Harari O. Liao J.K. Inhibition of MHC II gene transcription by nitric oxide and antioxidants Curr. Pharm. Des. 2004 10 893 898 10.2174/1381612043452893 15032692 PMC2633593 · DOI
  163. [176]Nagaraj S. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer Nat. Med. 2007 13 828 835 10.1038/nm1609 17603493 PMC2135607 · DOI
  164. [177]Lu T. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice J. Clin. Invest. 2011 121 4015 4029 10.1172/JCI45862 21911941 PMC3195459 · DOI
  165. [178]Kusmartsev S. Gabrilovich D.I. Inhibition of myeloid cell differentiation in cancer: The role of reactive oxygen species J. Leukoc. Biol. 2003 74 186 196 10.1189/jlb.0103010 12885935 · DOI
  166. [179]Kusmartsev S. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species J. Immunol. 2004 172 989 999 10.4049/jimmunol.172.2.989 14707072 · DOI
  167. [180]Molon B. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells J. Exp. Med. 2011 208 1949 1962 10.1084/jem.20101956 21930770 PMC3182051 · DOI
  168. [181]Beury D.W. Myeloid-Derived Suppressor Cell Survival and Function Are Regulated by the Transcription Factor Nrf2 J. Immunol. 2016 196 3470 3478 10.4049/jimmunol.1501785 26936880 PMC4821672 · DOI
  169. [182]Della Chiesa M. The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function Blood 2006 108 4118 4125 10.1182/blood-2006-03-006700 16902152 · DOI
  170. [183]Song H. L-kynurenine-induced apoptosis in human NK cells is mediated by reactive oxygen species Int. Immunopharmacol. 2011 11 932 938 10.1016/j.intimp.2011.02.005 21352963 · DOI
  171. [184]Fleming V. Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression Front. Immunol. 2018 9 398 10.3389/fimmu.2018.00398 29552012 PMC5840207 · DOI
  172. [185]Mezrich J.D. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells J. Immunol. 2010 185 3190 3198 10.4049/jimmunol.0903670 20720200 PMC2952546 · DOI
  173. [186]Fallarino F. T cell apoptosis by kynurenines Adv. Exp. Med. Biol. 2003 527 183 190 15206731
  174. [187]Curti A. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells Blood 2007 109 2871 2877 10.1182/blood-2006-07-036863 17164341 · DOI
  175. [188]Cheng P. S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes Leukemia 2019 33 2034 2046 10.1038/s41375-019-0397-9 30737486 PMC6687540 · DOI
  176. [189]Hart K.M. IL-10 immunomodulation of myeloid cells regulates a murine model of ovarian cancer Front. Immunol. 2011 2 29 10.3389/fimmu.2011.00029 22566819 PMC3342001 · DOI
  177. [190]Marvel D. Gabrilovich D.I. Myeloid-derived suppressor cells in the tumor microenvironment: Expect the unexpected J. Clin. Invest. 2015 125 3356 3364 10.1172/JCI80005 26168215 PMC4588239 · DOI
  178. [191]Messmer M.N. Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy Cancer Immunol. Immunother. 2015 64 1 13 10.1007/s00262-014-1639-3 25432147 PMC4282948 · DOI
  179. [192]Dolcetti L. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF Eur. J. Immunol. 2010 40 22 35 10.1002/eji.200939903 19941314 · DOI
  180. [193]Cuenca A.G. A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma Mol. Med. 2011 17 281 292 10.2119/molmed.2010.00178 21085745 PMC3060988 · DOI
  181. [194]Maenhout S.K. Enhanced suppressive capacity of tumor-infiltrating myeloid-derived suppressor cells compared with their peripheral counterparts Int. J. Cancer 2014 134 1077 1090 10.1002/ijc.28449 23983191 · DOI
  182. [195]Mantovani A. The growing diversity and spectrum of action of myeloid-derived suppressor cells Eur. J. Immunol. 2010 40 3317 3320 10.1002/eji.201041170 21110315 · DOI
  183. [196]Meyer C. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab Cancer Immunol. Immunother. 2014 63 247 257 10.1007/s00262-013-1508-5 24357148 PMC11029062 · DOI · Paper page
  184. [197]Tarhini A.A. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab PLoS ONE 2014 9 e87705 10.1371/journal.pone.0087705 24498358 PMC3912016 · DOI
  185. [198]Weber J. Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab Cancer Immunol. Res. 2016 4 345 353 10.1158/2326-6066.CIR-15-0193 26873574 PMC4818672 · DOI · Paper page
  186. [199]Groth C. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression Br. J. Cancer 2019 120 16 25 10.1038/s41416-018-0333-1 30413826 PMC6325125 · DOI
  187. [200]Suzuki E. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity Clin. Cancer Res. 2005 11 6713 6721 10.1158/1078-0432.CCR-05-0883 16166452 · DOI · Paper page
  188. [201]Sevko A. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model J. Immunol. 2013 190 2464 2471 10.4049/jimmunol.1202781 23359505 PMC3578135 · DOI
  189. [202]Eriksson E. Gemcitabine reduces MDSCs, tregs and TGFbeta-1 while restoring the teff/treg ratio in patients with pancreatic cancer J. Transl. Med. 2016 14 282 10.1186/s12967-016-1037-z 27687804 PMC5041438 · DOI
  190. [203]Vincent J. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity Cancer Res. 2010 70 3052 3061 10.1158/0008-5472.CAN-09-3690 20388795 · DOI · Paper page
  191. [204]Mikyskova R. Cyclophosphamide-induced myeloid-derived suppressor cell population is immunosuppressive but not identical to myeloid-derived suppressor cells induced by growing TC-1 tumors J. Immunother. 2012 35 374 384 10.1097/CJI.0b013e318255585a 22576342 · DOI
  192. [205]Iida Y. Contrasting effects of cyclophosphamide on anti-CTL-associated protein 4 blockade therapy in two mouse tumor models Cancer Sci. 2017 108 1974 1984 10.1111/cas.13337 28787548 PMC5623733 · DOI
  193. [206]Ko J.S. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients Clin. Cancer Res. 2009 15 2148 2157 10.1158/1078-0432.CCR-08-1332 19276286 · DOI
  194. [207]Kodera Y. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3 Breast Cancer Res. 2011 13 R66 10.1186/bcr2903 21693010 PMC3218955 · DOI
  195. [208]Qin H. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice Nat. Med. 2014 20 676 681 10.1038/nm.3560 24859530 PMC4048321 · DOI
  196. [209]Robinson S.C. A chemokine receptor antagonist inhibits experimental breast tumor growth Cancer Res. 2003 63 8360 8365 14678997
  197. [210]Velasco-Velazquez M. CCR5 antagonist blocks metastasis of basal breast cancer cells Cancer Res. 2012 72 3839 3850 10.1158/0008-5472.CAN-11-3917 22637726 · DOI
  198. [211]Toh B. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor PLoS Biol. 2011 9 e1001162 10.1371/journal.pbio.1001162 21980263 PMC3181226 · DOI
  199. [212]Zhu H. CXCR2(+) MDSCs promote breast cancer progression by inducing EMT and activated T cell exhaustion Oncotarget 2017 8 114554 114567 10.18632/oncotarget.23020 29383101 PMC5777713 · DOI
  200. [213]Di Mitri D. Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer Nature 2014 515 134 137 10.1038/nature13638 25156255 · DOI · Paper page

200 of 235 shown

Cited by

Sorted by citations

Authors
Law, A. M. K., Valdes-Mora, F., & Gallego-Ortega, D.
Affiliations
  • Garvan Institute of Medical Research (AU)
  • Histone Variants Group, Garvan Institute of Medical Research, Sydney, NSW 2010, Australia
  • Tumour Development Group, The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, NSW 2010, Australia
Corresponding author
Law, Andrew M. K.
ORCID
Venue
Cells
Publisher
MDPI AG
Published
2020-02-27
Volume
9
Issue
3
Pages
561
ISSN
2073-4409 (ISSN-L)
DOI
10.3390/cells9030561
PMC
PMC7140518
OpenAlex
W3010011098
Cited by
455
References
14
Citations by year
2026: 26 · 2025: 58 · 2024: 76 · 2023: 86 · 2022: 95 · 2021: 88 · 2020: 26
FWCI
7.32
Type
journal article
Language
en
Open access
Licence
Locations
  • Cells (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • OPUS - Open Publications of UTS Scholars (University of Technology Sydney) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Cancer Institute NSW (DG00625, CDF181218)
  • Cancer Council NSW (RG18-03)
  • Australian Government Research Training Program (-)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
myeloid-derived suppressor cells, cancer immunotherapy, immune checkpoint inhibitors, PD-1, CTLA-4, tumor microenvironment, immunosuppression, immunotherapy resistance, pre-metastatic niche, T cell suppression, NK cell inhibition, combination therapy
MeSH terms
Myeloid-Derived Suppressor Cells, Immune Checkpoint Inhibitors, Animals, Humans, Immunosuppression Therapy, Immunotherapy, Neoplasms, Carcinogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review